DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
25 hedge funds and large institutions have $14.9M invested in DMK Pharmaceuticals Corporation Common Stock in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 8 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
40% more capital invested
Capital invested by funds: $10.6M → $14.9M (+$4.27M)
11% less funds holding
Funds holding: 28 → 25 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$245K |
| 2 |
Walleye Trading
New York
|
+$86.2K |
| 3 |
Renaissance Technologies
New York
|
+$65.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58.6K |
| 5 |
SCM
Sio Capital Management
New York
|
+$53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$208K |
| 2 |
Goldman Sachs
New York
|
-$57K |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
-$48.9K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$40K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LOAMU
26
Lombard Odier Asset Management (USA)
New York
| – | -$208K | -753 | Closed |
|
|
27
Goldman Sachs
New York
| – | -$57K | -210 | Closed |
|
|
VKH
28
Virtu KCG Holdings
New York
| – | -$40K | -146 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$7K | -28 | Closed |
|
|
LFR
30
Lehman Financial Resources
Media,
Pennsylvania
| – | -$3K | -14 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$3K | -12 | Closed |
|
DMK Hedge Fund Activity: Q4 2015 in Review
25 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2015, worth a combined $14.9M — up 40% from $10.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DMK and 5 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $245K. The largest seller was Lombard Odier Asset Management (USA), exiting entirely with an estimated $208K sold.
- 25 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2015, down from 28 in Q3 2015.
- Funds reported $14.9M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2015, up 40% quarter-over-quarter.
- 5 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2015 and 8 closed out, a net change of -3 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2015 was Raymond James & Associates, an estimated $245K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2015 was Lombard Odier Asset Management (USA), an estimated $208K sold.
Based on aggregated 13F filings for Q4 2015.